LakeShore Biopharma Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
LakeShore Biopharma's earnings have been declining at an average annual rate of -45.1%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 15% per year.
Anahtar bilgiler
-45.1%
Kazanç büyüme oranı
-15.3%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | 15.0% |
Özkaynak getirisi | -74.1% |
Net Marj | -75.6% |
Son Kazanç Güncellemesi | 31 Mar 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Investors Don't See Light At End Of LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Tunnel And Push Stock Down 66%
Nov 01LakeShore Biopharma Co., Ltd (NASDAQ:LSB) Looks Inexpensive After Falling 36% But Perhaps Not Attractive Enough
Jun 25Little Excitement Around YS Biopharma Co., Ltd.'s (NASDAQ:YS) Revenues
May 08Gelir ve Gider Dağılımı
LakeShore Biopharma nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
31 Mar 24 | 573 | -433 | 435 | 303 |
31 Dec 23 | 544 | -334 | 427 | 342 |
30 Sep 23 | 561 | -309 | 373 | 374 |
30 Jun 23 | 658 | -195 | 363 | 349 |
31 Mar 23 | 687 | -145 | 339 | 319 |
31 Dec 22 | 698 | -95 | 370 | 265 |
30 Sep 22 | 633 | -72 | 350 | 211 |
30 Jun 22 | 574 | -103 | 317 | 219 |
31 Mar 22 | 503 | -106 | 279 | 211 |
31 Mar 21 | 257 | -192 | 225 | 94 |
Kaliteli Kazançlar: LSB is currently unprofitable.
Büyüyen Kar Marjı: LSB is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: Insufficient data to determine if LSB's year-on-year earnings growth rate was positive over the past 5 years.
Büyüme Hızlandırma: Unable to compare LSB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: LSB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: LSB has a negative Return on Equity (-74.07%), as it is currently unprofitable.